Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Three European entrepreneurs, all recently diagnosed with the rare and fatal neurodegenerative disease amyotrophic lateral sclerosis (ALS), have launched an investment fund to find a cure for their disease. The group has already initiated the world’s largest genetic research study related to the disease and now has turned its attention to translating disparate academic research into treatments. The entrepreneurs’ goal is to raise $140 million from “impact investors”—investors interested in social benefit alongside a financial return. The founders say the fund is the first to specifically target a rare disease.
This article has been sent to the following recipient: